{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:03:06Z","timestamp":1781658186445,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T00:00:00Z","timestamp":1511913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/leu.2017.338","type":"journal-article","created":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T07:41:02Z","timestamp":1513582862000},"page":"1016-1022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells"],"prefix":"10.1038","volume":"32","author":[{"given":"B","family":"Peter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Bibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Eisenwort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Wingelhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Stefanzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Blatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7409-4204","authenticated-orcid":false,"given":"E","family":"Hadzijusufovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Hoermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Jawhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Willmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W R","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8810-6835","authenticated-orcid":false,"given":"J","family":"Zuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Sotlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H-P","family":"Horny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0918-9463","authenticated-orcid":false,"given":"R","family":"Moriggl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,29]]},"reference":[{"key":"BFleu2017338_CR1","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1111\/1523-1747.ep12468882","volume":"96","author":"DD Metcalfe","year":"1991","unstructured":"Metcalfe DD . Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991; 96: 2S\u20134S.","journal-title":"J Invest Dermatol"},{"key":"BFleu2017338_CR2","first-page":"385","volume":"108","author":"P Valent","year":"1996","unstructured":"Valent P . Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr 1996; 108: 385\u2013397.","journal-title":"Wien Klin Wochenschr"},{"key":"BFleu2017338_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0145-2126(01)00021-2","volume":"25","author":"HP Horny","year":"2001","unstructured":"Horny HP, Valent P . Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001; 25: 543\u2013551.","journal-title":"Leuk Res"},{"key":"BFleu2017338_CR4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00277-002-0575-z","volume":"81","author":"L Escribano","year":"2002","unstructured":"Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD . Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002; 81: 677\u2013690.","journal-title":"Ann Hematol"},{"key":"BFleu2017338_CR5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","volume":"122","author":"P Valent","year":"2003","unstructured":"Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122: 695\u2013717.","journal-title":"Br J Haematol"},{"key":"BFleu2017338_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","volume":"55","author":"C Akin","year":"2004","unstructured":"Akin C, Metcalfe DD . Systemic mastocytosis. Annu Rev Med 2004; 55: 419\u2013432.","journal-title":"Annu Rev Med"},{"key":"BFleu2017338_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MOH.0b013e3283366c59","volume":"17","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, Tefferi A . Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol 2010; 17: 125\u2013132.","journal-title":"Curr Opin Hematol"},{"issue":"Suppl 2","key":"BFleu2017338_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.0960-135X.2004.01369.x","volume":"34","author":"P Valent","year":"2004","unstructured":"Valent P, Ghannadan M, Akin C, Krauth MT, Selzer E, Mayerhofer M et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest 2004; 34 (Suppl 2): 41\u201352.","journal-title":"Eur J Clin Invest"},{"key":"BFleu2017338_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/00062752-200401000-00009","volume":"11","author":"A Tefferi","year":"2004","unstructured":"Tefferi A, Pardanani A . Clinical genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 2004; 11: 58\u201364.","journal-title":"Curr Opin Hematol"},{"key":"BFleu2017338_CR10","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","volume":"92","author":"H Nagata","year":"1995","unstructured":"Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560\u201310564.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2017338_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000048179","volume":"127","author":"F Feger","year":"2002","unstructured":"Feger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M . Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002; 127: 110\u2013114.","journal-title":"Int Arch Allergy Immunol"},{"key":"BFleu2017338_CR12","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/ng0396-312","volume":"12","author":"BJ Longley","year":"1996","unstructured":"Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12: 312\u2013314.","journal-title":"Nat Genet"},{"key":"BFleu2017338_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1046\/j.1365-2141.2001.02783.x","volume":"113","author":"R Fritsche-Polanz","year":"2001","unstructured":"Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001; 113: 357\u2013364.","journal-title":"Br J Haematol"},{"key":"BFleu2017338_CR14","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/leu.2015.24","volume":"29","author":"M Arock","year":"2015","unstructured":"Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia 2015; 29: 1223\u20131232.","journal-title":"Leukemia"},{"key":"BFleu2017338_CR15","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1172\/JCI116761","volume":"92","author":"T Furitsu","year":"1993","unstructured":"Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J Clin Invest 1993; 92: 1736\u20131744.","journal-title":"J Clin Invest"},{"key":"BFleu2017338_CR16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","volume":"108","author":"NP Shah","year":"2006","unstructured":"Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C . Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108: 286\u2013291.","journal-title":"Blood"},{"key":"BFleu2017338_CR17","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","volume":"31","author":"C Akin","year":"2003","unstructured":"Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003; 31: 686\u2013692.","journal-title":"Exp Hematol"},{"key":"BFleu2017338_CR18","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3324\/haematol.11339","volume":"92","author":"KV Gleixner","year":"2007","unstructured":"Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 2007; 92: 1451\u20131459.","journal-title":"Haematologica"},{"key":"BFleu2017338_CR19","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","volume":"107","author":"KV Gleixner","year":"2006","unstructured":"Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, B\u00f6hm A et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006; 107: 752\u2013759.","journal-title":"Blood"},{"key":"BFleu2017338_CR20","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","volume":"106","author":"J Gotlib","year":"2005","unstructured":"Gotlib J, Berub\u00e9 C, Growney JD, Chen CC, George TI, Williams C et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 2865\u20132870.","journal-title":"Blood"},{"key":"BFleu2017338_CR21","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","volume":"374","author":"J Gotlib","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 2016; 374: 2530\u20132541.","journal-title":"N Engl J Med"},{"key":"BFleu2017338_CR22","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","volume":"118","author":"KV Gleixner","year":"2011","unstructured":"Gleixner KV, Mayerhofer M, Cerny-Reiterer S, H\u00f6rmann G, Rix U, Bennett KL et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and BTK activation and disruption by dasatinib and bosutinib. Blood 2011; 118: 1885\u20131898.","journal-title":"Blood"},{"key":"BFleu2017338_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3324\/haematol.2010.031690","volume":"96","author":"TM Wilson","year":"2011","unstructured":"Wilson TM, Maric I, Simakova O, Bai Y, Chan EC, Olivares N et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2011; 96: 459\u2013463.","journal-title":"Haematologica"},{"key":"BFleu2017338_CR24","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","volume":"122","author":"J Schwaab","year":"2013","unstructured":"Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013; 122: 2460\u20132466.","journal-title":"Blood"},{"key":"BFleu2017338_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.iac.2014.01.009","volume":"34","author":"S Bibi","year":"2014","unstructured":"Bibi S, Langenfeld F, Jeanningros S, Brenet F, Soucie E, Hermine O et al. Molecular defects in mastocytosis: KIT and beyond KIT. Immunol Allergy Clin North Am 2014; 34: 239\u2013262.","journal-title":"Immunol Allergy Clin North Am"},{"key":"BFleu2017338_CR26","doi-asserted-by":"publisher","first-page":"e85362","DOI":"10.1371\/journal.pone.0085362","volume":"9","author":"G Damaj","year":"2014","unstructured":"Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS ONE 2014; 9: e85362.","journal-title":"PLoS ONE"},{"key":"BFleu2017338_CR27","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.2353\/ajpath.2009.080953","volume":"175","author":"C Baumgartner","year":"2009","unstructured":"Baumgartner C, Cerny-Reiterer S, Sonneck K, Mayerhofer M, Gleixner KV, Fritz R et al. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol 2009; 175: 2416\u20132429.","journal-title":"Am J Pathol"},{"key":"BFleu2017338_CR28","doi-asserted-by":"publisher","first-page":"5956","DOI":"10.1074\/jbc.M110.182642","volume":"286","author":"A Chaix","year":"2011","unstructured":"Chaix A, Lopez S, Voisset E, Gros L, Dubreuil P, De Sepulveda P . Mechanisms ofSTAT protein activation by oncogenic KIT mutants in neoplastic mast cells. J Biol Chem 2011; 286: 5956\u20135966.","journal-title":"J Biol Chem"},{"key":"BFleu2017338_CR29","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1182\/blood-2007-09-115477","volume":"112","author":"N Harir","year":"2008","unstructured":"Harir N, Boudot C, Friedbichler K, Sonneck K, Kondo R, Martin-Lanner\u00e9e S et al. Oncogenic Kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signalling cascade. Blood 2008; 112: 2463\u20132473.","journal-title":"Blood"},{"key":"BFleu2017338_CR30","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2141.2011.08898.x","volume":"155","author":"SS Farag","year":"2011","unstructured":"Farag SS . The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol 2011; 155: 561\u2013579.","journal-title":"Br J Haematol"},{"key":"BFleu2017338_CR31","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/sj.cr.7310046","volume":"16","author":"XX Wang","year":"2006","unstructured":"Wang XX, Liu R, Jin SQ, Fan FY, Zhan QM . Overexpression of Aurora-A kinase promotes tumor cell proliferation and inhibits apoptosis in esophageal squamous cell carcinoma cell line. Cell Res 2006; 16: 356\u2013366.","journal-title":"Cell Res"},{"key":"BFleu2017338_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/CAD.0b013e3283350dd1","volume":"21","author":"W Lok","year":"2010","unstructured":"Lok W, Klein RQ, Saif MW . Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs 2010; 21: 339\u2013350.","journal-title":"Anticancer Drugs"},{"key":"BFleu2017338_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00432-009-0641-1","volume":"136","author":"J McLaughlin","year":"2010","unstructured":"McLaughlin J, Markovtsov V, Li H, Wong S, Gelman M, Zhu Y et al. Preclinical characterization of Aurora kinase inhibitor R763 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol 2010; 136: 99\u2013113.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFleu2017338_CR34","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00432-016-2136-1","volume":"142","author":"J Cicenas","year":"2016","unstructured":"Cicenas J . The Aurora kinase inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 2016; 142: 1995\u20132012.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFleu2017338_CR35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny H-P, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Conference Report of \u2018Year 2000 Working Conference on Mastocytosis\u2019 Leuk Res 2001; 25: 603\u2013625.","journal-title":"Leuk Res"},{"key":"BFleu2017338_CR36","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","volume":"129","author":"P Valent","year":"2017","unstructured":"Valent P, Akin C, Metcalfe DD . Mastocytosis: 2016-updated WHO classification and novel emerging treatment concepts. Blood 2017; 129: 1420\u20131427.","journal-title":"Blood"},{"key":"BFleu2017338_CR37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","volume":"12","author":"JH Butterfield","year":"1988","unstructured":"Butterfield JH, Weiler D, Dewald G, Gleich GJ . Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988; 12: 345\u2013355.","journal-title":"Leuk Res"},{"key":"BFleu2017338_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood-2013-10-534685","volume":"124","author":"R Saleh","year":"2014","unstructured":"Saleh R, Wedeh G, Herrmann H, Bibi S, Cerny-Reiterer S, Sadovnik I et al. A new human mast cell line expressing a functional IgE receptor converts to factor-independence and tumorigenicity by KIT D816V-transfection. Blood 2014; 124: 111\u2013120.","journal-title":"Blood"},{"key":"BFleu2017338_CR39","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1096\/fj.14-250894","volume":"28","author":"G Hoermann","year":"2014","unstructured":"Hoermann G, Blatt K, Greiner G, Putz EM, Berger A, Herrmann H et al. CD52 is a molecular target in advanced systemic mastocytosis. FASEB J 2014; 28: 3540\u20133551.","journal-title":"FASEB J"},{"key":"BFleu2017338_CR40","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1165\/ajrcmb\/3.5.413","volume":"3","author":"R DeVinney","year":"1990","unstructured":"DeVinney R, Gold WM . Establishment of two dog mastocytoma cell lines in continuous culture. Am J Respir Cell Mol Biol 1990; 3: 413\u2013420.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"BFleu2017338_CR41","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/j.1398-9995.2012.02833.x","volume":"67","author":"E Hadzijusufovic","year":"2012","unstructured":"Hadzijusufovic E, Peter B, Herrmann H, R\u00fclicke T, Cerny-Reiterer S, Schuch K, Kenner L, Thaiwong T, Yuzbasiyan-Gurkan V, Pickl WF, Willmann M, Valent P . NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. Allergy 2012; 67: 858\u2013868.","journal-title":"Allergy"},{"key":"BFleu2017338_CR42","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3324\/haematol.2010.031328","volume":"96","author":"B Peter","year":"2011","unstructured":"Peter B, Gleixner KV, Cerny-Reiterer S, Herrmann H, Winter V, Hadzijusufovic E et al. Polo-like kinase-1 as novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of siRNA and the Polo-like kinase-1 targeting drug BI 2536. Haematologica 2011; 96: 672\u2013680.","journal-title":"Haematologica"},{"key":"BFleu2017338_CR43","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1074-7613(00)80097-7","volume":"11","author":"R Moriggl","year":"1999","unstructured":"Moriggl R, Sexl V, Piekorz R, Topham D, Ihle JN . Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. Immunity 1999; 11: 225\u2013230.","journal-title":"Immunity"},{"key":"BFleu2017338_CR44","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/hep.24765","volume":"55","author":"K Friedbichler","year":"2012","unstructured":"Friedbichler K, Themanns M, Mueller KM, Schlederer M, Kornfeld JW, Terracciano LM et al. Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. Hepatology 2012; 55: 941\u2013952.","journal-title":"Hepatology"},{"key":"BFleu2017338_CR45","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1038\/leu.2015.138","volume":"29","author":"G Wedeh","year":"2015","unstructured":"Wedeh G, Cerny-Reiterer S, Eisenwort G, Herrmann H, Blatt K, Hadzijusufovic E et al. Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia. Leukemia 2015; 29: 2230\u20132237.","journal-title":"Leukemia"},{"key":"BFleu2017338_CR46","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.celrep.2013.11.020","volume":"5","author":"C Fellmann","year":"2013","unstructured":"Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep 2013; 5: 1704\u20131713.","journal-title":"Cell Rep"},{"key":"BFleu2017338_CR47","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1096\/fj.11-193078","volume":"26","author":"G Hoermann","year":"2012","unstructured":"Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H et al. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokineproduction and bone marrow remodeling in myeloproliferative neoplasms. FASEB J 2012; 26: 894\u2013906.","journal-title":"FASEB J"},{"issue":"1","key":"BFleu2017338_CR48","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/vco.12311","volume":"16","author":"Alexandra Keller","year":"2017","unstructured":"Keller A, Wingelhofer B, Peter B, Bauer K, Berger D, Gamperl S et al. The JAK2\/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma. Vet Comp Oncol 2017; epub ahead of print 11 April 2017 doi:10.1111\/vco.12311.","journal-title":"Veterinary and Comparative Oncology"},{"key":"BFleu2017338_CR49","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2015.242","volume":"30","author":"B Peter","year":"2016","unstructured":"Peter B, Winter GE, Blatt K, Bennett KL, Stefanzl G, Rix U et al. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia 2016; 30: 464\u2013472.","journal-title":"Leukemia"},{"key":"BFleu2017338_CR50","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2174\/18715230113129990002","volume":"12","author":"A Tob\u00edo","year":"2013","unstructured":"Tob\u00edo A, Alfonso A, Fern\u00e1ndez-Araujo A, Alonso E, Botana LM . Protein kinase C modulates Aurora-kinase inhibition induced by CCT129202 in HMC-1560, 816 cell line. Antiinflamm Antiallergy Agents Med Chem 2013; 12: 265\u2013276.","journal-title":"Antiinflamm Antiallergy Agents Med Chem"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017338","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:11:14Z","timestamp":1684433474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,29]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["BFleu2017338"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.338","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,29]]},"assertion":[{"value":"20 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GH received honoraria from Novartis and Ariad. WRS received honoraria from Novartis and Celgene, and a research grant from Lipomed. PV, H-PH and AR served as a Consultant in a global Novartis trial examining the effects of midostaurin in advanced SM. JZ received institutional support from Boehringer-Ingelheim, and is consultant and stock holder at Mirimus Inc. AR received a research grant from Novartis, honoraria from Novartis and BMS, and served in advisory boards organized by Novartis. MA received research grants from Blueprint and Deciphera, and received honoraria from Deciphera. PV received research grants from Novartis, Blueprint and Deciphera, and honoraria from Novartis, Celgene, Pfizer and Deciphera. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}